Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
University Hospital Heidelberg · Humboldt-Universität zu Berlin · +39 more institutions
Abstract
Tebentafusp, a T-cell receptor-bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are positive for HLA-A*02:01 and have unresectable or metastatic uveal melanoma. The primary analysis in the present phase 3 trial supported a long-term survival benefit associated with the drug.
We report the 3-year efficacy and safety results from our open-label, phase 3 trial in which HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma were randomly assigned in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with pembrolizumab, ipilimumab, or dacarbazine (control group), with randomization stratified according to the lactate dehydrogenase level. The primary end point was overall survival.
Citation impact
- FWCI
- 64.19
- Percentile
- 100%
- References
- 23
Authors
29- JCJessica C. HasselCorresponding
University Hospital Heidelberg, Humboldt-Universität zu Berlin, Ludwig-Maximilians-Universität München, Heidelberg University
- SPSophie Piperno‐Neumann
Humboldt-Universität zu Berlin, Institut Curie, University Hospital Heidelberg, Ludwig-Maximilians-Universität München, Heidelberg University
- PRPiotr Rutkowski
The Maria Sklodowska-Curie National Research Institute of Oncology, Ludwig-Maximilians-Universität München, University Hospital Heidelberg, Heidelberg University, Humboldt-Universität zu Berlin
- JBJean‐François Baurain
University Hospital Heidelberg, UCLouvain, Heidelberg University, Humboldt-Universität zu Berlin, Princess Margaret Cancer Centre, Cliniques Universitaires Saint-Luc, Ludwig-Maximilians-Universität München
- MSMax Schlaak
University Hospital Heidelberg, Charité - Universitätsmedizin Berlin, Heidelberg University, Ludwig-Maximilians-Universität München, Freie Universität Berlin, Humboldt-Universität zu Berlin
Topics & keywords
- Melanoma
- Medicine
- Oncology
- Internal medicine
- Metastatic melanoma
- Dermatology
- Cancer research
- Good health and well-being